Repatha (Evolocumab) Dose Adjustments for South Asian Patients
Evidence-based guide to evolocumab (Repatha) dosing considerations for South Asian patients, covering pharmacogenomics, cardiovascular risk profiles, and clinical trial subgroup data.
5 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.

Showing 5 of 5 clinical reviews.
Evidence-based guide to evolocumab (Repatha) dosing considerations for South Asian patients, covering pharmacogenomics, cardiovascular risk profiles, and clinical trial subgroup data.
A clinician-focused review of evolocumab (Repatha) efficacy, pharmacogenomics, and dosing considerations in East Asian patients, including FOURIER subgroup data, PharmGKB annotations, and population PK differences.
A clinician-focused guide to evolocumab (Repatha) dosing in East Asian patients, covering pharmacogenomics, ethnicity-stratified FOURIER subgroup data, PK modeling, and guideline recommendations.
Evidence-based guide to evolocumab (Repatha) dosing, pharmacogenomics, and clinical outcomes in Hispanic and Latino patients, including ethnicity-stratified FOURIER subgroup data and PharmGKB guidance.
A detailed clinical review of evolocumab (Repatha) safety, pharmacogenomics, and dosing considerations in South Asian patients, including FOURIER subgroup data, PCSK9 variant frequencies, and cardiovascular risk context.